Travere Therapeutics Inc (TVTX): Next-Year EPS Estimate 660.70%
As of 2026-05-20, Travere Therapeutics Inc (TVTX) has a next-year EPS growth estimate of 660.70%. Featured in 2 EPS revision reports, most recently on 2026-04-15.
On 2026-05-17, analyst consensus for TVTX's next-year EPS growth shifted from 636.10% to 660.70% — a positive change of 24.60 percentage points. The revised estimate has been sustained across 4 subsequent trading sessions. Current-year growth is projected at 216.61%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 660.70%
- EPS growth this year
- 216.61%
- EPS next quarter (est)
- -$0.05
- Last price
- $43.49
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-05-20 | 660.70% | 216.61% | -$0.05 | $43.49 |
| 2026-05-19 | 660.70% | 216.61% | -$0.05 | $42.26 |
| 2026-05-18 | 660.70% | 216.61% | -$0.05 | $42.89 |
| 2026-05-17 | 660.70% | 216.61% | -$0.05 | $42.59 |
| 2026-05-14 | 636.10% | 215.60% | -$0.05 | $44.10 |
| 2026-05-13 | 636.10% | 215.60% | -$0.05 | $44.48 |
| 2026-05-12 | 636.10% | 215.60% | -$0.05 | $42.84 |
| 2026-05-11 | 636.10% | 215.60% | -$0.05 | $43.51 |
| 2026-05-10 | 636.10% | 215.60% | -$0.05 | $42.60 |
| 2026-05-07 | 636.10% | 215.60% | -$0.05 | $42.66 |
| 2026-05-06 | 636.10% | 215.60% | -$0.05 | $44.76 |
| 2026-05-05 | 660.36% | 211.14% | -$0.06 | $44.80 |
| 2026-05-04 | 686.24% | 200.71% | -$0.24 | $44.91 |
| 2026-05-03 | 686.24% | 200.71% | -$0.24 | $44.12 |
| 2026-04-30 | 686.24% | 200.71% | -$0.24 | $42.12 |
| 2026-04-29 | 690.56% | 196.20% | -$0.24 | $40.10 |
| 2026-04-28 | 690.56% | 196.20% | -$0.24 | $40.89 |
| 2026-04-27 | 690.56% | 196.20% | -$0.24 | $40.81 |
| 2026-04-26 | 634.79% | 200.98% | -$0.23 | $40.50 |
| 2026-04-24 | 634.79% | 200.98% | -$0.23 | $40.50 |
| 2026-04-23 | 630.85% | 200.98% | -$0.23 | $40.82 |
| 2026-04-22 | 630.85% | 200.98% | -$0.23 | $40.09 |
| 2026-04-21 | 630.85% | 200.98% | -$0.23 | $38.78 |
| 2026-04-20 | 633.84% | 199.92% | -$0.23 | $40.29 |
| 2026-04-19 | 633.84% | 199.92% | -$0.23 | $40.77 |
| 2026-04-16 | 633.31% | 199.92% | -$0.23 | $39.54 |
| 2026-04-15 | 633.31% | 199.92% | -$0.23 | $40.95 |
| 2026-04-14 | 622.52% | 201.46% | -$0.23 | $42.13 |
| 2026-04-13 | 545.76% | 213.57% | -$0.23 | $30.70 |
| 2026-04-12 | 548.79% | 213.04% | -$0.23 | $28.96 |
Reports Featuring TVTX
Recent News
- Four Biotech Stocks Near Buy Points As Earnings Season Kicks InInvestor's Business Daily
Screen Performance
Aggregate stats across all 1713 tickers our top-EPS-revision screen has flagged over the past 49 days.
- Median return since detection
- +2.8%
- % of tickers in the green
- 58%
- Median return on winners
- +15.1%
- Large revisions captured
- 630
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Travere Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-05-20, Travere Therapeutics Inc (TVTX) has a next-year EPS growth estimate of 660.70%, based on analyst consensus.
When was the latest EPS estimate revision for TVTX?▾
The most recent revision occurred on 2026-05-17, when analysts adjusted the next-year EPS growth estimate from 636.10% to 660.70%.
What sector and industry does Travere Therapeutics Inc belong to?▾
Travere Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. TVTX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Travere Therapeutics Inc (TVTX) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports